



#14

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known			
		Application Number	09/807,462		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	April 11, 2001		
		First Named Inventor	Beth A. BURNSIDE et al.		
		Group Art Unit	1617		
		Examiner Name	Alysia Berman		
Sheet	1	of	1	Attorney Docket Number	PHARMA-142P1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	1 ✓	K. S. PATRICK et al., "Pharmacology of Methylphenidate, Amphetamine Enantiomers and Pemoline in Attention-Deficit..." HUMAN PSYCHOPHARMACOLOGY, Vol. 12, pp. 527-546, 1997.	
✓	2 ✓	Lisa H. BRAUER et al., "Acute Tolerance to Subjective but Not Cardiovascular Effects of d-Amphetamine in Normal, Healthy Men," JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, Vol. 16, No. 1, pp. 72-76, 1996.	
✓	3 ✓	William P. MELEGA et al., "Pharmacokinetic and Pharmacodynamic Analysis of the Actions of D-Amphetamine and D-Methamphetamine on the Dopamine Terminal," THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Vol. 274, No. 1, pp. 90-96, 1995	
✓	4 ✓	Peter CLAUSING et al., "Amphetamine Levels in Brain Microdialysate, Caudate/Putamen, Substantia Nigra and Plasma After Dosage That Produces Either Behavioral..." THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Vol. 274, No. 2, pp. 614-621, 1995.	
✓	5 ✓	S.B. SPARBER et al., "Amphetamine Cumulation and Tolerance Development: Concurrent and Opposing Phenomena," PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR, Vol. 20, pp. 415-424, 1984.	
✓	6 ✓	Burt ANGRIST et al., "Early Pharmacokinetics and Clinical Effects of Oral D-Amphetamine in Normal Subjects," BIOL PSYCHIATRY, Vol. 22, pp. 1357-1368, 1987..	
✓	7 ✓	Gerald L. BROWN et al., "Plasma Levels of d-Amphetamine in Hyperactive Children," PSYCHOPHARMACOLOGY, Vol. 62, pp. 133-140, 1979.	
✓	8 ✓	Suk Han WAN et al., "Kinetics, Salivary Excretion of Amphetamine Isomers, and Effect of Urinary pH," CLIN. PHARMACOL. THER., pp. 585-590, May 1978.	
	9	Gerald L. BROWN et al., "Plasma d-Amphetamine Absorption and Elimination in Hyperactive Children," PSYCHOPHARMACOLOGY BULLETIN, Vol. 14, No. 3, pp. 33-35, 1978.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.